01 · ABSTRACT
Abstract
Since the emergence of SARS-CoV-2 infection in Wuhan, China, in December 2019, the spread has caused COVID19 disease in over 8.1 million people and more than 439 thousand deaths across the globe as on 16th June 2020. Absence of any particular cure or vaccine lead the health care system to treat the patients with the existing potential antiviral drugs. Recently, Favipiravir, a potential RdRp inhibitor of SARS-COV-2 sheds the ray of hope for treating COVID-19 patients efficiently.
02 · PUBLICATION RECORD
Article details
JournalMedical Research Archives
IssueVol 8 No 8 (2020): Vol.8 Issue 8, August 2020
SectionReview Articles
Published24 August 2020
DOI10.18103/mra.v8i8.2210
ISSN2375-1924
03 · RIGHTS & REUSE
Rights & reuse
This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.